AHA 2025 7 - 10 November 2025

Semaglutide 2.4 mg Real-world Risk Reduction of Cardiometabolic Comorbidities and Improvement in Biomarkers among Patients with Overweight or Obesity (SMILE)

Authors :

Aleksandrina Ruseva¹; Matthew Bassan¹; Ella Xiaoyan Du²; Anthony Fabricatore¹; Briain O Hartaigh¹; Wojciech Michalak¹; Ramya Ramasubramanian²; Pangsibo Shen²; Jinlin Song²; Zhenxiang Zhao¹; Francisco Lopez-Jimenez³

Affiliations

View Details Hide Details

Keywords

Obesity

Congress poster

GLP-1 RA

Semaglutide

RWE HEOR

Search Science Hub

Are you a healthcare professional?

Semaglutide 2.4 mg Real-world Risk Reduction of Cardiometabolic Comorbidities and Improvement in Biomarkers among Patients with Overweight or Obesity (SMILE)